Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for TNX-102 SL in Post-Traumatic Stress Disorder
August 29, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Regulatory Acceptance of Phase 3 Program and Product Registration Plan Dosing in First Phase 3 Trial Expected to Commence in the First Quarter of 2017 NEW YORK, Aug. 29, 2016 (GLOBE NEWSWIRE) --...
Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium
August 15, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update
August 08, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
First Phase 3 Study of TNX-102 SL in Fibromyalgia to Report Topline Results in September NEW YORK, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix),...
Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
July 26, 2016 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
July 12, 2016 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 12, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced that the underwriters of Tonix’s previously announced public offering that...
Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
July 07, 2016 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, July 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
June 21, 2016 12:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 21, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of...
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
June 17, 2016 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 17, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress...
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
June 16, 2016 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 16, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 5,000,000 shares of its...
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 15, 2016 16:01 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, June 15, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced that it intends to offer shares of its common stock in an underwritten public...